Manufacturer of Controlled Substances; Notice of Registration, 2324-2325 [2012-658]
Download as PDF
<![CDATA[
2324
Federal Register / Vol. 77, No. 10 / Tuesday, January 17, 2012 / Notices
Dated: January 6, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
[FR Doc. 2012–679 Filed 1–13–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a), of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on September 6, 2011
Cedarburg Pharmaceuticals, Inc., 870
Badger Circle, Grafton, Wisconsin
53024, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
Drug
Schedule
4–Anilino-N-phenethyl-4-piperidine (8333).
Fentanyl (9801) ............................
II
II
srobinson on DSK4SPTVN1PROD with NOTICES
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
Regarding the drug code (8333), the
company plans to use this controlled
substance to manufacture another
controlled substance.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than March 19, 2012.
Dated: January 6, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–656 Filed 1–13–12; 8:45 am]
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on September 12,
2011, Johnson Matthey, Inc.,
Pharmaceuticals Materials, 900 River
Road, Conshohocken, Pennsylvania
19428, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
Drug
Gamma Hydroxybutyric Acid
(2010) ................................
Amphetamine (1100) ............
Methylphenidate (1724) ........
Codeine (9050) .....................
Oxycodone (9143) ................
Hydrocodone (9193) .............
Morphine (9300) ...................
Thebaine (9333) ...................
The company plans to manufacture
the listed controlled substances in bulk
for sale in bulk to its customers. The
Thebaine (9333) will also be used to
manufacture other controlled substances
in bulk which will also be for sale in
bulk to its customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than March 19, 2012.
Dated: January 6, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
16:12 Jan 13, 2012
Jkt 226001
Schedule
Marihuana (7360) .................
Tetrahydrocannabinols
(7370) ................................
I
II
II
II
II
II
II
II
Dated: January 6, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–663 Filed 1–13–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
BILLING CODE 4410–09–P
Drug Enforcement Administration
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
PO 00000
Frm 00068
Fmt 4703
Sfmt 4703
I
I
The company plans to manufacture
bulk active pharmaceutical ingredients
(APIs) for distribution to its customers.
In reference to drug code 7360
(Marihuana), the company plans to bulk
manufacture cannabidiol as a synthetic
intermediate. This controlled substance
will be further synthesized to bulk
manufacture a synthetic THC (7370). No
other activity for this drug code is
authorized for this registration.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Austin Pharma LLC. to manufacture the
listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Austin Pharma LLC. to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
[FR Doc. 2012–653 Filed 1–13–12; 8:45 am]
By Notice dated August 9, 2011, and
published in the Federal Register on
August 18, 2011, 76 FR 51401, Austin
VerDate Mar<15>2010
Drug
Schedule
Manufacturer of Controlled
Substances; Notice of Registration
BILLING CODE 4410–09–P
Pharma LLC., 811 Paloma Drive, Suite
C, Round Rock, Texas 78665–2402,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
DEPARTMENT OF JUSTICE
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated August 10, 2011, and
published in the Federal Register on
August 18, 2011, 76 FR 51401, AMRI
Rensselaer, Inc., 33 Riverside Avenue,
Rensselaer, New York 12144, made
application by renewal to the Drug
E:\FR\FM\17JAN1.SGM
17JAN1
Federal Register / Vol. 77, No. 10 / Tuesday, January 17, 2012 / Notices
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Drug
Schedule
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Amphetamine (1100) ....................
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Pentobarbital (2270) .....................
Meperidine (9230) ........................
4–Anilino-N-phenethyl-4-piperidine (8333).
Fentanyl (9801) ............................
I
I
II
II
II
II
II
II
srobinson on DSK4SPTVN1PROD with NOTICES
BILLING CODE 4410–09–P
VerDate Mar<15>2010
16:12 Jan 13, 2012
Jkt 226001
Solicitation for a Cooperative
Agreement—Jail Resource
Management: Review and Revision
National Institute of
Corrections, U.S. Department of Justice.
ACTION: Solicitation for a Cooperative
Agreement.
The National Institute of
Corrections (NIC) is seeking
applications for the revision of its Jail
Resource Management training program.
The project will be for a 9-month period
and will be carried out in conjunction
with the NIC Jails Division. The
awardee will work closely with NIC
staff on all aspects of the project. To be
considered, applicants must
demonstrate, at a minimum, in-depth
knowledge of (1) the purpose, functions,
and operational complexities of local
jails, (2) budget issues common in jails,
(3) analysis of jail resource needs, (4)
development and presentation of a
budget request to appropriate governing
bodies, (5) budget management, and (6)
the resource constraints faced by many
local governments and their jails. Also,
the applicant must demonstrate
expertise and experience in developing
curricula based on adult learning
principles, specifically the Instructional
Theory into Practice (ITIP) model.
DATES: Applications must be received
by 4 p.m. (EDT) on Thursday, February
9, 2012.
ADDRESSES: Mailed applications must be
sent to: Director, National Institute of
Corrections, 320 First Street NW., Room
5002, Washington, DC 20534.
Applicants are encouraged to use
Federal Express, UPS, or similar service
to ensure delivery by the due date as
mail at NIC is sometimes delayed due to
security screening.
Applicants who wish to hand-deliver
their applications should bring them to
500 First Street NW., Washington, DC
20534, and dial (202) 307–3106, ext. 0,
at the front desk for pickup.
Faxed or emailed applications will
not be accepted; however, electronic
applications can be submitted via https://
www.grants.gov.
FOR FURTHER INFORMATION CONTACT: A
copy of this announcement and the
required application forms can be
downloaded from the NIC Web site at
www.nicic.gov/cooperativeagreements.
Questions about this project and the
application procedures should be
directed to Erika McDuffe, Correctional
Program Specialist, National Institute of
Corrections. Questions must be emailed
SUMMARY:
The company plans to manufacture
bulk controlled substances for use in
product development and for
distribution to its customers.
In reference to drug code 7360
(Marihuana), the company plans to bulk
manufacture cannabidiol as a synthetic
intermediate. This controlled substance
will be further synthesized to bulk
manufacture a synthetic THC (7370). No
other activity for this drug code is
authorized for this registration.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
AMRI Rensselaer, Inc. to manufacture
the listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated AMRI Rensselaer, Inc. to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
[FR Doc. 2012–658 Filed 1–13–12; 8:45 am]
National Institute of Corrections
AGENCY:
II
Dated: January 6, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
DEPARTMENT OF JUSTICE
PO 00000
Frm 00069
Fmt 4703
Sfmt 4703
2325
to Ms. McDuffe at emcduffe@bop.gov.
Ms. McDuffe will respond by email to
the individual. Also, all questions and
responses will be posted on NIC’s Web
site at www.nicic.gov for public review.
(The names of those submitting the
questions will not be posted.) The Web
site will be updated regularly and
postings will remain on the Web site
until the closing date of this cooperative
agreement solicitation.
SUPPLEMENTARY INFORMATION:
Background: NIC’s Jail Resource
Management course is a 3-day training
program that focuses on the resource
needs of the jail, development and
presentation of a budget request,
management of the budget, and
identification of alternate funding
options. This 3-day program is held in
regions throughout the county.
Program participants are primarily
sheriffs and administrators from smaller
jails who have no specialized fiscal
management staff. Most have no
formally established mechanisms to
identify, document, track, justify, or
present resource needs. As a result, their
jails often receive budget allocations
that are inadequate to maintain a safe
and secure jail.
NIC wishes to update the content of
Jail Resource Management and ensure
its design conforms to the ITIP model.
The following reference materials are
posted with this announcement on
NIC’s Web site: Jail Resource
Management: Lesson Plans; Jail
Resource Management: Participant
Manual; Jail Resource Management:
Presentation Slides; Jail Resource
Management: Activities.
Scope of Work: The cooperative
agreement awardee will revise the
content of the current program to ensure
it is current, accurate, and relevant. The
awardee also will ensure that module
sequencing is logical and enhances the
flow of the program. Finally, the
awardee will revise the program’s
design to conform to the ITIP model.
The awardee will ensure that content,
module sequencing, and instructional
strategies effectively contribute to
meeting the program’s goal. To achieve
this, the awardee will complete the
following activities, at a minimum.
Initial Meeting: The cooperative
agreement awardee, with subject matter
expert and the curriculum specialist,
will attend an initial meeting with the
NIC staff for a project overview and
preliminary planning. This will take
place shortly after the cooperative
agreement is awarded. The meeting will
last up to one half day and will be
conducted via Web conferencing.
Initial curriculum review: The
awardee will review and become
E:\FR\FM\17JAN1.SGM
17JAN1
]]>Agencies
[Federal Register Volume 77, Number 10 (Tuesday, January 17, 2012)]
[Notices]
[Pages 2324-2325]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-658]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated August 10, 2011, and published in the Federal
Register on August 18, 2011, 76 FR 51401, AMRI Rensselaer, Inc., 33
Riverside Avenue, Rensselaer, New York 12144, made application by
renewal to the Drug
[[Page 2325]]
Enforcement Administration (DEA) to be registered as a bulk
manufacturer of the following basic classes of controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Marihuana (7360)........................... I
Tetrahydrocannabinols (7370)............... I
Amphetamine (1100)......................... II
Lisdexamfetamine (1205).................... II
Methylphenidate (1724)..................... II
Pentobarbital (2270)....................... II
Meperidine (9230).......................... II
4-Anilino-N-phenethyl-4-piperidine (8333).. II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to manufacture bulk controlled substances for use
in product development and for distribution to its customers.
In reference to drug code 7360 (Marihuana), the company plans to
bulk manufacture cannabidiol as a synthetic intermediate. This
controlled substance will be further synthesized to bulk manufacture a
synthetic THC (7370). No other activity for this drug code is
authorized for this registration.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
AMRI Rensselaer, Inc. to manufacture the listed basic classes of
controlled substances is consistent with the public interest at this
time. DEA has investigated AMRI Rensselaer, Inc. to ensure that the
company's registration is consistent with the public interest. The
investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with state and local laws, and a review of the company's background and
history.
Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR
1301.33, the above named company is granted registration as a bulk
manufacturer of the basic classes of controlled substances listed.
Dated: January 6, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2012-658 Filed 1-13-12; 8:45 am]
BILLING CODE 4410-09-P
